When a generic drug company in New Jersey files an Abbreviated New Drug Application with the FDA, it enters a […]
Two Roads to Generic Entry: Why the EU Refuses America’s Patent Linkage System Read Post »
The Doctrine That Kept Generics Alive—Until It Didn’t For decades, the skinny label was the workhorse of generic drug market
Skinny Labels Are Now a Liability: How GSK v. Teva Rewrote Generic Drug Strategy Read Post »
The pharmaceutical industry operates on an honor system that is finally collapsing. For decades, the Food and Drug Administration (FDA)
The 180-day exclusivity period is the most significant financial incentive in the United States pharmaceutical regulatory framework. This six-month window
180-Day Exclusivity: How It’s Triggered and Tracked in the FDA Orange Book Read Post »
The pharmaceutical market is a system of state-sanctioned monopolies and sudden, catastrophic revenue collapses. At the center of this system
The most profitable legal monopoly in the United States does not belong to a tech giant with a locked-down ecosystem
Own the Biologic Drug Moat: The 12-Year Monopoly Playbook Read Post »
The U.S. Food and Drug Administration (FDA) maintains a registry that dictates the cash flow of the global pharmaceutical industry.
Profit From Weak Drug Patents: Identifying Weak Patent Listings in the FDA Orange Book Read Post »
The valuation of a pharmaceutical enterprise often rests less on the efficacy of its molecules than on the strength of
Paragraph IV Strategy: Extracting Litigation Signals from the FDA Orange Book Read Post »
The pharmaceutical industry enters a period of unprecedented revenue contraction as the 2025-2030 patent cliff approaches. Analysis of current market
Sell More Packaging Before Patents Die: Target drug companies shifting to OTC post-LOE Read Post »
Sign in or create a free account to read this DrugPatentWatch article
